RxDoctor Payments Data

Min Song, MD

Internal Medicine · New York, NYNPI 1467483917

Payments from drug & device makers

$3,368in general payments, 2019–2025

Across 44 payments — averaging $76.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$560
  • AbbVie$435
  • Neurocrine Biosciences, Inc.$334
  • Novo Nordisk$250
  • Merck$234
  • Axsome Therapeutics, Inc.$220
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$3,368100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,368 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$30,404
Medicare patients
33
Services billed
369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol110$104,950
VemlidyTenofovir Alafenamide50$69,501
JardianceEmpagliflozin68$68,251
JanumetSitagliptin Phos/Metformin Hcl54$63,508
JanuviaSitagliptin Phosphate66$60,534
Diclofenac Epolamine73$50,885
RybelsusSemaglutide34$45,737
VascepaIcosapent Ethyl120$34,546
EliquisApixaban42$32,336
TrulicityDulaglutide31$30,820
XareltoRivaroxaban23$21,953
TradjentaLinagliptin14$15,619
JentaduetoLinagliptin/Metformin Hcl11$14,256
MounjaroTirzepatide11$13,976
Janumet XrSitagliptin Phos/Metformin Hcl21$10,964

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanumet, Januvia, Janumet Xr$234$135,006141 claims
GileadVemlidy$560$69,50150 claims
Novo NordiskRybelsus$250$45,73734 claims
Lilly USA, LLCTrulicity, Mounjaro$125$44,79642 claims
Johnson & JohnsonXarelto$102$21,95323 claims
GSKShingrix, Arexvy$121$18,772101 claims
NovartisEntresto$117$8,51513 claims
AbbVieLinzess, Synthroid$435$7,76238 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →